blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3119199

EP3119199 - COMPOUNDS AND THEIR METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.01.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  14.02.2020
FormerGrant of patent is intended
Status updated on  08.10.2019
FormerExamination is in progress
Status updated on  27.02.2019
FormerRequest for examination was made
Status updated on  23.12.2016
FormerThe international publication has been made
Status updated on  14.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139 / US
[2017/04]
Inventor(s)01 / CIANCHETTA, Giovanni
28 Copley Avenue
Waltham, MA 02452 / US
02 / LEMIEUX, Rene, M.
3 Essex Street
No. 14
Charlestown, MA 02129 / US
03 / CAO, Sheldon
Xialian Village
Xukou Town Fuyang City 311404 / CN
04 / DING, Yue
888 Luojin Road
Shanghai 201104 / CN
05 / YE, Zhixiong
No.4 Yuyang Road
Yosemite C-2012
Beijing 101302 / CN
 [2017/04]
Representative(s)Bassil, Nicholas Charles
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2020/12]
Former [2017/04]Bassil, Nicholas Charles
Kilburn & Strode LLP
20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date15764391.720.03.2015
[2017/04]
WO2015US21781
Priority number, dateWO2014CN7381221.03.2014         Original published format: PCT/CN2014/073812
[2017/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015143340
Date:24.09.2015
Language:EN
[2015/38]
Type: A1 Application with search report 
No.:EP3119199
Date:25.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.09.2015 takes the place of the publication of the European patent application.
[2017/04]
Type: B1 Patent specification 
No.:EP3119199
Date:18.03.2020
Language:EN
[2020/12]
Search report(s)International search report - published on:US24.09.2015
(Supplementary) European search report - dispatched on:EP18.10.2017
ClassificationIPC:A01N43/40, A61K31/44, A61K31/50
[2017/04]
CPC:
C07D417/08 (EP,US); C07D403/08 (EP,KR,US); A61K31/501 (KR);
A61P35/00 (EP); A61P43/00 (EP); C07D237/14 (EP,US);
C07D237/20 (EP,KR,US); C07D401/12 (EP,US); C07D401/14 (EP,KR,US);
C07D403/12 (EP,US); C07D403/14 (EP,KR,US); C07D405/12 (EP,US);
C07D405/14 (EP,KR,US); C07D409/12 (EP,US); C07D409/14 (EP,KR,US);
C07D413/12 (EP,US); C07D413/14 (EP,US); C07D417/12 (EP,US);
C07D417/14 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/04]
Extension statesBA10.10.2016
ME10.10.2016
Validation statesMA10.10.2016
TitleGerman:VERBINDUNGEN UND VERFAHREN ZU DEREN VERWENDUNG[2017/04]
English:COMPOUNDS AND THEIR METHODS OF USE[2017/04]
French:COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS[2017/04]
Entry into regional phase10.10.2016National basic fee paid 
10.10.2016Search fee paid 
10.10.2016Designation fee(s) paid 
10.10.2016Examination fee paid 
Examination procedure10.10.2016Examination requested  [2017/04]
10.10.2016Date on which the examining division has become responsible
17.05.2018Amendment by applicant (claims and/or description)
04.03.2019Despatch of a communication from the examining division (Time limit: M04)
26.06.2019Reply to a communication from the examining division
09.10.2019Communication of intention to grant the patent
06.02.2020Fee for grant paid
06.02.2020Fee for publishing/printing paid
06.02.2020Receipt of the translation of the claim(s)
Opposition(s)21.12.2020No opposition filed within time limit [2021/08]
Fees paidRenewal fee
27.03.2017Renewal fee patent year 03
27.03.2018Renewal fee patent year 04
27.03.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.03.2015
AL18.03.2020
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MK18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
IE20.03.2020
LU20.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
[2022/31]
Former [2022/30]HU20.03.2015
AL18.03.2020
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
IE20.03.2020
LU20.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2022/27]HU20.03.2015
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
IE20.03.2020
LU20.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/24]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
IE20.03.2020
LU20.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/10]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
IE20.03.2020
LU20.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/09]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
IE20.03.2020
LU20.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/08]CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
IE20.03.2020
LU20.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/07]CZ18.03.2020
DK18.03.2020
EE18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
IE20.03.2020
LU20.03.2020
CH31.03.2020
LI31.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/04]CZ18.03.2020
EE18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
LU20.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/50]CZ18.03.2020
EE18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/49]CZ18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/48]FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/47]FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
Former [2020/46]FI18.03.2020
HR18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
Former [2020/45]FI18.03.2020
HR18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
Former [2020/39]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
Former [2020/38]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
NO18.06.2020
GR19.06.2020
Former [2020/37]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
NO18.06.2020
Former [2020/35]FI18.03.2020
NO18.06.2020
Documents cited:Search[XI]WO2013078123  (CALITHERA BIOSCIENCES INC [US], et al) [X] 1-7 * claim 1 * [I] 8-17;
 [XP]WO2014079150  (AGIOS PHARMACEUTICALS INC [US], et al) [XP] 1 * claim 1 *;
 [A]  - HEMANT PANWAR ET AL, "Studies on Some Bioactive 1,1-Bis(2-benzylidene-5-aryliden-1,3-thiadiazolidin-4-one)cyclopropane", JOURNAL OF THE KOREAN CHEMICAL SOCIETY., KR, (20111220), vol. 55, no. 6, doi:10.5012/jkcs.2011.55.6.994, ISSN 1017-2548, pages 994 - 999, XP055258415 [A] 1-17 * abstract *

DOI:   http://dx.doi.org/10.5012/jkcs.2011.55.6.994
International search[A]WO9422842  (BASF AG [DE]) [A] 18-20 * ; page 7, lines 28-29; page 138 lines 7275 *;
 [A]WO2006040569  (ASTEX THERAPEUTICS LTD [GB], et al) [A] 2 * ; page 101, lines 1-5 *;
 [YA]WO2008048967  (UNIV ROCHESTER [US], et al) [Y] 1, 10, 13 * ; paragraph [0042]; daim 2 * [A] 9, 11-12, 14-20;
 [A]WO2012120428  (NOVARTIS AG [CH], et al) [A] 8 * ; page 47, lines 1-10 *;
 [A]WO2012171337  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-20* ; entire publication *;
 [X]  - PubChem., (20071205), Database accession no. 22812110., XP055226931 [X] 1, 3, 5-7 * ; page 1 *
 [YA]  - PubChem., (20121130), Database accession no. 66760293, XP055226934 [Y] 1, 4 * ; page 1 * [A] 8, 17-20
 [YA]  - PubChem., (20070209), Database accession no. 13735314., XP055226940 [Y] 1, 10, 13 * ; page 1 * [A] 2, 11, 12, 14-16
 [A]  - PubChem., (20120820), Database accession no. 59841146., XP055226943 [A] 9, 12, 14-16 * ; page 1 *
by applicantUS4366241
 US4376110
 US4517288
 US4837168
 US4843155
 WO2013078123
 WO2014079150
    - YAUCH et al., Clin Cancer Res, (20050000), vol. 11, page 24
    - SAVAGNER et al., Ann Oncol., (20100000), vol. 21, no. 7, page vii89
    - THIERY et al., Nature Reviews Cancer, (20020000), vol. 2, no. 6, page 442
    - ASAI, Methods in Cell Biology, (19930000), vol. 37
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.